Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
Cristiano Caruso, Paolo Cameli, Elena Altieri, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 11

Showing 11 citing articles:

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme
David J. Jackson, Girolamo Pelaia, Benjamin Emmanuel, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 1, pp. 2301521-2301521
Open Access | Times Cited: 19
Benralizumab for eosinophilic granulomatosis with polyangiitis
Adrien Cottu, Matthieu Groh, Charlene Desaintjean, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 12, pp. 1580-1586
Closed Access | Times Cited: 24
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
Alessandra Vultaggio, Maria Aliani, Elena Altieri, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 20
Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study
Alicia Padilla, Isabel Carmona, Pilar Ausín, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 20
Switching Biological Therapies in Severe Asthma
Giulia Scioscia, Santi Nolasco, Raffaele Campisi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9563-9563
Open Access | Times Cited: 16
Biologics for severe asthma and beyond
Carlo Mümmler, Katrin Milger
Pharmacology & Therapeutics (2023) Vol. 252, pp. 108551-108551
Closed Access | Times Cited: 9
Advancing Care in Severe Asthma: The Art of Switching Biologics
Silvano Dragonieri, Andrea Portacci, Vitaliano Nicola Quaranta, et al.
Advances in respiratory medicine (2024) Vol. 92, Iss. 2, pp. 110-122
Open Access | Times Cited: 2
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
Paolo Cameli, Maria Aliani, Elena Altieri, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 273-290
Open Access | Times Cited: 2
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
Giulia Scioscia, Pasquale Tondo, Santi Nolasco, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4362-4362
Open Access | Times Cited: 6
Pharmacologic Treatment of Type 2-High Severe Asthma
Annamaria Bosi, Maria Serena Simeone, Federica Ghinassi, et al.
Medical Research Archives (2024) Vol. 12, Iss. 4
Open Access
Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response
Mona Al‐Ahmad, Asmaa Ali, Ahmed Maher
Medical Principles and Practice (2023) Vol. 32, Iss. 6, pp. 323-331
Open Access | Times Cited: 1
Page 1

Scroll to top